Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

Company News

As of June 9, 2025 • 10:01 PM ET

Date/Time Source News Release
12/10/2021 07:01 AM EST GlobeNewswire XORTX Therapeutics Announces Publication of Mt. Sinai Study of Hospitalized COVID-19 Patients
12/09/2021 08:03 AM EST GlobeNewswire XORTX Announces Research Coverage Initiated by A.G.P./Alliance Global Partners
12/02/2021 07:00 AM EST GlobeNewswire XORTX Therapeutics Appoints Altasciences as CRO for Clinical Study
11/23/2021 07:00 AM EST GlobeNewswire XORTX Therapeutics Announces Annual and Special Meeting of Shareholders
11/09/2021 07:00 AM EST GlobeNewswire XORTX Therapeutics Announces Partial Exercise of Over-Allotment Option Pursuant to US Public Offering
11/04/2021 02:48 PM EDT GlobeNewswire XORTX Therapeutics Clarifies Halt of Trading in Canada and Timing for Commencement of Trading on TSX Venture Exchange
11/04/2021 02:11 PM EDT Newsfile CSE Bulletin: Delist - XORTX Therapeutics Inc. (XRX)
11/02/2021 06:13 PM EDT GlobeNewswire XORTX Therapeutics Receives Final Approval to List on the TSX Venture Exchange
10/15/2021 05:38 PM EDT GlobeNewswire XORTX Therapeutics Announces Closing of US$12 Million Public Offering
10/14/2021 05:30 PM EDT GlobeNewswire XORTX Announces Results from Mount Sinai's COVID-19 Clinical Study
Page

Additional News

As of June 9, 2025 • 10:01 PM ET

Date/Time Source News Release
02/22/2021 09:00 AM EST Stockhouse Bio-Pharma Co. Announces Granting of European Patent for Treating Kidney Disease
08/19/2020 09:26 AM EDT Livemoney XORTX Therapeutics Moves Toward Phase 3 Trials to Help with an "Orphan" Kidney Disease and COVID-19 Kidney Injuries
07/15/2019 01:15 PM EDT Stockhouse Leading Publication Covers XORTX Kidney Disease Therapies
Page
  • 1

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.